Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
Portfolio Pulse from Vandana Singh
Bristol Myers Squibb (BMY) reported strong Q3 results with revenues of $11.89 billion, surpassing expectations. The growth was driven by high demand for its Growth Portfolio, including drugs like Reblozyl and Eliquis. The company raised its 2024 outlook, expecting revenue growth of around 6%.
October 31, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb reported Q3 revenues of $11.89 billion, exceeding expectations, driven by strong demand for its Growth Portfolio, including Eliquis and Reblozyl. The company raised its 2024 outlook, expecting revenue growth of around 6%.
Bristol Myers Squibb's strong Q3 performance, driven by high demand for key drugs, led to a revenue beat and an optimistic 2024 outlook. This positive financial performance and outlook are likely to boost investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100